Long-term maintenance of the anabolic effects of GH on the skeleton in successful treated patients with acromegaly

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 53-60

  Biermasz, Nienke R ^a   Hamdy, Neveen A T ^a   Pereira, Alberto M ^a   Romijn, Johannes A ^a   Roelfsema, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYPOPHYSIS HORMONE; OCTREOTIDE; SEX HORMONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGE; ARTICLE; BIOSYNTHESIS; BONE DENSITY; BONE MASS; BONE MINERAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICAL BONE; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; ENDOCRINE SURGERY; FEMALE; FEMUR NECK; GONAD; GROWTH HORMONE RELEASE; HEALTH CARE POLICY; HORMONE DEFICIENCY; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOGONADISM; IRRADIATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; OSTEOLYSIS; OSTEOPOROSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SKELETON; TIME; TRABECULAR BONE; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE REMODELING; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; HYDROXYPROLINE; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OCTREOTIDE; OSTEOCALCIN; SKELETON;

EID: 13244275291     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01820     Document Type: Article

References (39)

1. Albright F & Reifenstein ECJ. The Parathyroid Glands and Metabolic Bone Disease. Selected Studies, pp 188-196. Baltimore: Williams & Wilkins, 1948.
2. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT & Slootweg MC. Growth hormone and bone. Endocrine Reviews 1998 19 55-79.
3. Scillitani A, Battista C, Chiodini I, Carnevale V, Fusilli S, Ciccarelli E, Terzolo M, Oppizzi G, Arosio M, Gasperi M, Arnaldi G, Colao A, Baldelli R, Ghiggi MR, Gaia D, Di Somma C, Trischitta V & Liuzzi A. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clinical Endocrinology (Oxford) 2003 58 725-731.
4. Chiodini I, Trischitta V, Carnevale V, Liuzzi A & Scillitani A. Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis? Journal of Endocrinological Investigation 2001 24 288-291.
5. Janssen YJ, Frolich M & Roelfsema F. A low starting dose of genotropin in growth hormone-deficient adults. Journal of Clinical Endocrinology and Metabolism 1997 82 129-135.
6. Biermasz NR, van Dulken H & Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 2476-2482.
7. Biermasz NR, Dekker FW, Pereira AM, Van Thiel SW, Schutte PJ, van Dulken H, Romijn JA & Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. Journal of Clinical Endocrinology and Metabolism 2004 89 2789-2796.
8. Biermasz NR, van Dulken H & Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 4596-4602.
9. Biermasz NR, Thiel van SW, Pereira AM, Hoftijzer HC, Hemert AM, Smit JW, Romijn JA & Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of GH excess. Journal of Clinical Endocrinology and Metabolism 2004 89 5369-5376.
10. Prockop DJ & Udenfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Analytical Biochemistry 1960 1 228-239.
11. Wahner HW, Looker A, Dunn WL, Walters LC, Hauser MF & Novak C. Quality control of bone densitometry in a national health survey (NHANES III) using three mobile examination centers. Journal of Bone and Mineral Research 1994 9 951-960.
12. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S & Van Kuijk C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. Journal of Bone and Mineral Research 1994 9 1503-1514.
13. Staal KP, Roos JC, Manoliu RA, Kostense PJ & Lips P. Variations in diagnostic performances of dual-energy X-ray absorptiometry in the northwest of The Netherlands. Osteoporosis International 2004 15 335-344.
14. Kotzmann H, Bernecker P, Hubsch P, Pietschmann P, Woloszezuk W, Svoboda T, Geyer G & Luger A. Bone mineral density and parameters of bone metabolism in patients with acromegaly. Journal of Bone and Mineral Research 1993 8 459-465.
15. Lesse GP, Fraser WD, Farquharson R, Hipkin L & Vora JP. Gonadal status is an important determinant of bone density in acromegaly. Clinical Endocrinology (Oxford) 1998 48 59-65.
16. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H & Chihara K. Bone metabolism and body composition in Japanese patients with active acromegaly. Clinical Endocrinology (Oxford) 2001 55 175-181.
17. Ho PJ, Fig LM, Barkan AL & Shapiro B. Bone mineral density of the axial skeleton in acromegaly. Journal of Nuclear Medicine 1992 33 1608-1612.
18. Kayath MJ & Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporosis International 1997 7 226-230.
19. Diamond T, Nery L & Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Annals of Internal Medicine 1989 111 567-573.
20. Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D & Reiners C. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. European Journal of Medical Research 1996 1 377-382.
21. Bolanowski M, Wielgus W, Milewicz A & Marciniak R. Axial bone mineral density in patients with acromegaly. Academic Radiology 2000 7 592-594.
22. Roelfsema F. Quantitation of bone turnover in biopsy specimens from the iliac crest in acromegaly and Cushing's syndrome. In Proceedings of the first workshop on bone morphology. Ed. ZFG Jaworsky. Ottowa: University of Ottowa Press, 1976.
23. Broulik P, Kragstrup J, Mosekilde L & Melsen F. Osteon cross-sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 1982 90 339-344.
24. Halse J, Melsen F & Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinologica (Copenh) 1981 97 18-22.
25. Roelfsema F, Van der Sluys Veer J & Smeenk D. Quantitation of bone and bone turnover in biospsy specimens from the iliac crest in acromegaly. Irish Journal of Medical Science 1970 7 498.
26. Ueland T, Ebbesen EN, Thomsen JS, Mosekilde L, Brixen K, Flyvbjerg A & Bollerslev J. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. European Journal of Clinical Investigation 2002 32 122-128.
27. Bravenboer N, Holzmann P, de Boer H, Roos JC, van der Veen EA & Lips P. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. Journal of Clinical Endocrinology and Metabolism 1997 82 1818-1822.
28. Andreassen TT, Jorgensen PH, Flyvbjerg A, Orskov H & Oxlund H. Growth hormone stimulates bone formation and strength of cortical bone in aged rats. Journal of Bone and Mineral Research 1995 10 1057-1067.
29. Andreassen TT, Melsen F & Oxlund H. The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats. Journal of Bone and Mineral Research 1996 11 1094-1102.
30. Morimoto I, Kai K, Okada Y, Okimoto N, Uriu K, Akino K, Yamashita S, Nakamura T & Eto S. Skeletal changes in rats bearing mammosomatotrophic pituitary tumors: a model of acromegaly with gonadal dysfunction. Bone 2000 26 255-261.
31. Vestergaard P & Mosekilde L. Fracture risk is decreased in acromegaly - a potential beneficial effect of growth hormone. Osteoporosis International 2004 15 155-159.
32. Manolagas SC, Kousteni S & Jilka RL. Sex steroids and bone. Recent Progress in Hormone Research 2002 57 385-409.
33. Scillitani A, Chiodini I, Carnevale V, Giannatempo GM, Frusciante V, Villella M, Pileri M, Guglielmi G, Di Giorgio A, Modoni S, Fusilli S, Di Cerbo A & Liuzzi A. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. Journal of Bone and Mineral Research 1997 12 1729-1736.
34. Terzolo M, Piovesan A, Osella G, Pia A, Reimondo G, Puzzi C, Raucci C, Torta M, Paccotti P & Angeli A. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment. Calcified Tissue International 1993 52 188-191.
35. Legovini P, Menis de E, Breda F, Billeci D, Carteri A, Pavan P & Conte N. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. Journal of Endocrinological Investigation 1997 20 434-438.
36. de la Piedra C, Carbo E, Larranaga J, Castro N, Horcajada C, Rapado A & Herredo Pombo JL. Correlation among plasma octeocalcin, growth hormone, and somatomedin C in acromegaly. Calcified Tissue International 1988 43 44-45.
37. Ezzat S, Melmed S, Endres D, Eyre DR & Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. Journal of Clinical Endocrinology and Metabolism 1993 76 1452-1457.
38. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D & Klibanski A. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clinical Endocrinology (Oxford) 2002 57 385-390.
39. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P & Wuster C. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European Journal of Endocrinology 2002 146 67-74.